Drug Price Trends for RELPAX

Average Pharmacy Cost for RELPAX

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
RELPAX 40 MG TABLET	00049-2340-45	77.45713	EACH	2025-03-19
RELPAX 20 MG TABLET	00049-2330-45	77.57364	EACH	2025-03-19
RELPAX 40 MG TABLET	00049-2340-79	77.45713	EACH	2025-03-19
RELPAX 40 MG TABLET	58151-0368-96	77.45713	EACH	2025-03-19
RELPAX 20 MG TABLET	00049-2330-79	77.57364	EACH	2025-03-19

Market Analysis and Price Projections for Relpax (Eletriptan)

Overview of Relpax

Relpax, known generically as eletriptan, is a second-generation triptan drug used for the treatment of acute migraine headaches. It belongs to the class of selective serotonin receptor agonists, which work by acting on specific receptors in the brain to alleviate migraine symptoms[2].

Market Size and Growth

The global market for eletriptan, under the trade name Relpax, is part of the broader anti-migraine drugs market. As of 2023, the global eletriptan market was valued at USD 108 million and is forecasted to reach USD 141.4 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 3.9% during the review period[2].

Drivers of Market Growth

Several factors drive the growth of the eletriptan market:

• Increasing Prevalence of Migraines: The rising global prevalence of migraines, a common neurological disorder affecting millions, increases the demand for effective treatments like eletriptan[2].
• Targeted and Specific Treatments: The market is driven by the demand for more targeted and specific migraine treatments. Eletriptan's effectiveness in relieving migraines through its selective action on serotonin receptors contributes significantly to this demand[2].
• Healthcare Expenditure and Access: Improving healthcare infrastructure and increasing healthcare expenditure in emerging economies enhance the awareness and availability of migraine treatments, including eletriptan[2].

Market Competition

The eletriptan market is competitive, with several key players involved:

• API Manufacturers: Companies like Amneal Pharmaceuticals, Apotex, and Ajanta Pharma are significant API manufacturers for eletriptan. These companies play a crucial role in the supply chain and market dynamics[2].
• Generic Versions: The availability of generic versions of eletriptan has increased competition, offering consumers more affordable options. For instance, generic eletriptan prices start from around $105.68 for 6 tablets, significantly lower than the branded version[5].

Price Analysis

The cost of Relpax can vary based on the dosage and the pharmacy:

• Branded Relpax: The cost for Relpax 40 mg oral tablets is approximately $520 for a supply of 6 tablets. This price is for cash-paying customers and does not apply to those with insurance plans[5].
• Generic Eletriptan: Generic versions are available at a lower price, starting from $105.68 for 6 tablets. This makes the generic option more accessible to a wider range of consumers[5].

Forecasted Sales and Market Projections

Historical and forecasted sales data indicate steady growth for Relpax:

• Historical Sales: The report by DelveInsight provides historical global sales data for Relpax, which helps in understanding the drug's market performance over the years[1][4].
• Forecasted Sales: The sales of Relpax are estimated to continue growing, driven by the increasing demand for migraine treatments. The forecast period from 2019 to 2021 showed promising growth, and this trend is expected to continue up to 2030[1][2].

Regulatory and Patent Landscape

Understanding the regulatory and patent landscape is crucial for market projections:

• Patent Expiry and Exclusivity: The patent expiry timeline and market exclusivity data are critical for planning generic development and market entry strategies. The report by DelveInsight provides detailed information on these aspects[1][4].
• Regulatory Milestones: Regulatory approvals and milestones by region are essential for understanding the drug's market penetration and potential growth areas[4].

SWOT Analysis and Emerging Therapies

A SWOT analysis helps in identifying the strengths, weaknesses, opportunities, and threats for Relpax:

• Strengths: Effective in relieving migraine symptoms, targeted action on serotonin receptors, and established market presence.
• Weaknesses: High cost compared to generic versions, potential side effects, and competition from emerging therapies.
• Opportunities: Growing demand for migraine treatments, improving healthcare infrastructure, and potential for drug repurposing.
• Threats: Competition from new CGRP inhibitors and monoclonal antibody therapies, which are changing the migraine treatment landscape[1][3].

Emerging Therapies

The launch of new prophylactic drugs, such as CGRP-targeted monoclonal antibodies, is expected to significantly impact the migraine market:

"The launch of the CGRP inhibitors marked the biggest shakeup in the migraine market. The acute migraine market is mainly driven by the oral CGRP antagonists, which could double in size over the forecast period"[3].

These emerging therapies pose a threat to traditional triptan drugs like Relpax but also indicate a large unmet need for preventative therapy, which could drive overall market growth.

Key Takeaways

• The global eletriptan market is growing, driven by increasing migraine prevalence and demand for targeted treatments.
• The market is competitive, with both branded and generic versions available.
• Price variations exist between branded and generic options, affecting consumer choice.
• Regulatory and patent landscapes are crucial for market strategy.
• Emerging therapies like CGRP inhibitors are changing the market dynamics.

FAQs

What is Relpax used for?

Relpax (eletriptan) is used for the treatment of acute migraine headaches. It is an abortive medication that blocks a migraine attack already in progress[2].

How much does Relpax cost?

The cost for Relpax 40 mg oral tablets is approximately $520 for a supply of 6 tablets. Generic versions are available at a lower price, starting from $105.68 for 6 tablets[5].

What are the key drivers of the eletriptan market?

The key drivers include the increasing prevalence of migraines, demand for targeted and specific treatments, and improving healthcare expenditure and access in emerging economies[2].

What is the forecasted growth of the eletriptan market?

The global eletriptan market is forecasted to grow from USD 108 million in 2023 to USD 141.4 million by 2030, with a CAGR of 3.9% during the review period[2].

How do emerging therapies impact the Relpax market?

Emerging therapies like CGRP inhibitors and monoclonal antibodies are changing the migraine treatment landscape, posing a threat to traditional triptan drugs like Relpax but also indicating a large unmet need for preventative therapy[3].

Sources

1. DelveInsight, "Relpax Drug Insight, 2019" - ASDReports.
2. Global Info Research, "Global Eletriptan Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030".
3. iHealthcareAnalyst, "Global Anti-migraine Drugs Market $25.1 Billion by 2031".
4. ResearchAndMarkets.com, "Relpax - Drug Insight, 2019".
5. Drugs.com, "Relpax Prices, Coupons, Copay Cards & Patient Assistance".